期刊
CURRENT NEUROPHARMACOLOGY
卷 20, 期 3, 页码 611-629出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X19666210524154519
关键词
Erythropoietin; neuroprotective agent; pre-myelinating oligodendrocytes; premature brain injury; white matter injury; perinatal neuroinflammation
资金
- National key research and development plan key special project of digital diagnosis and treating equipment [2018YFC0114405]
This review investigates the role of erythropoietin (Epo) in the prevention of brain injury in preterm infants. Various animal models have shown that Epo has multiple protective effects. However, it is still too early to recommend Epo as the standard treatment for preterm brain injury.
Preterm infants are at high risk of brain injury. With more understanding of the preterm brain injury's pathogenesis, neuroscientists are looking for more effective methods to prevent and treat it, among which erythropoietin (Epo) is considered as a prime candidate. This review tries to clarify the possible mechanisms of Epo in preterm neuroprotection and summarize updated evidence considering Epo as a pharmacological neuroprotective strategy in animal models and clinical trials. To date, various animal models have validated that Epo is an anti-apoptotic, anti-inflammatory, anti-oxidant, anti-excitotoxic, neurogenetic, erythropoietic, angiogenetic, and neurotrophic agent, thus preventing preterm brain injury. However, although the scientific rationale and preclinical data for Epo's neuroprotective effect are promising, when translated to bedside, the results vary in different studies, especially in its long-term efficacy. Based on existing evidence, it is still too early to recommend Epo as the standard treatment for preterm brain injury.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据